Expanding universal testing to all HER2-negative BC patients is cost-effective
HER2-negative, TNBC, TNBCs
Considering the tremendous cost-effectiveness of universal testing in all TNBCs, we then expanded the indication of this policy from TNBC to all HER2-negative patients. The universal testing contributed 87.6 and 57.0 days of life expectancy gained in Chinese HER2-negative BC patients compared with patients receiving no testing and the selected testing (Table 